Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AMAM
- Price
- -
- Stock movement up
- +0.02 (0.07%)
- Company name
- Ambrx Biopharma Inc. American Depositary Shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.77B
- Ent value
- 1.58B
- Price/Sales
- 514.40
- Price/Book
- 7.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 123.29%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2024-12-16
DIVIDENDS
AMAM does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 514.40 |
| Price to Book | 7.31 |
| EV to Sales | 457.46 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.29M |
| EPS (TTM) | -1.11 |
| FCF per share (TTM) | -0.96 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.44M |
| Gross profit (TTM) | 3.44M |
| Operating income (TTM) | -69.50M |
| Net income (TTM) | -69.37M |
| EPS (TTM) | -1.11 |
| EPS (1y forward) | -1.56 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -2017.33% |
| Profit margin (TTM) | -2013.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 225.26M |
| Net receivables | 2.36M |
| Total current assets | 233.82M |
| Goodwill | 0.00 |
| Intangible assets | 24.78M |
| Property, plant and equipment | 18.81M |
| Total assets | 271.50M |
| Accounts payable | 5.14M |
| Short/Current long term debt | 10.52M |
| Total current liabilities | 18.27M |
| Total liabilities | 29.10M |
| Shareholder's equity | 242.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -57.70M |
| Capital expenditures (TTM) | 1.91M |
| Free cash flow (TTM) | -59.61M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -28.62% |
| Return on Assets | -25.55% |
| Return on Invested Capital | -28.39% |
| Cash Return on Invested Capital | -24.40% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| AMAM | S&P500 | |
| Current price drop from All-time high | -0.32% | -0.60% |
| Highest price drop | -98.18% | -19.00% |
| Date of highest drop | 8 Dec 2022 | 8 Apr 2025 |
| Avg drop from high | -58.02% | -2.49% |
| Avg time to new high | 57 days | 6 days |
| Max time to new high | 626 days | 89 days |
COMPANY DETAILS
Marketcap
1.77B
Marketcap category
Small-cap
Description
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
Employees
87
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner